Jyoti Malhotra, MD, MPH

In this companion article, Dr. Jyoti Malhotra discusses her clinical experience using trilaciclib for the management of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer.

In the third video of the series, Dr. Jyoti Malhotra from the Rutgers Cancer Institute of New Jersey shares expert insights on the benefits of using trilaciclib in clinical practice including considerations for chemotherapy treatment efficacy and patient quality of life. As of May 1, 2022, Dr. Malhotra is no longer with Rutgers Cancer Institute; she is now affiliated with City of Hope.

Jyoti Malhotra, MD, MPH, discusses the preliminary efficacy signals of the combination therapy plinabulin, nivolumab, and ipilimumab in patients with relapsed/refractory small cell lung cancer.